AMBS:OTC-Amarantus BioScience Holdings, Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.01

Change

0.00 (0.00)%

Market Cap

USD 3.34M

Volume

0.42M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

USD164.65B 24.98 2.76
CMXHF CSL Limited

N/A

USD97.05B 42.41 25.71
CSLLY CSL Limited

N/A

USD95.30B 43.19 25.71
GNMSF Genmab A/S

N/A

USD23.27B 25.66 2.93
UCBJF UCB SA

N/A

USD22.12B 24.73 18.77
UCBJY UCB SA

N/A

USD21.81B 24.83 18.77
SBHMY Sino Biopharmaceutical Limited

N/A

USD21.38B 56.11 3.56
SBMFF Sino Biopharmaceutical Limited

N/A

USD20.54B 59.30 3.56
PPTDF PeptiDream Inc

N/A

USD5.14B 260.99 1.35
MPSYF MorphoSys AG

N/A

USD4.05B 32.27 28.84

ETFs Containing AMBS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.14% 28% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.14% 27% F 35% F
Trailing 12 Months  
Capital Gain -23.31% 33% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.31% 32% F 36% F
Trailing 5 Years  
Capital Gain -99.17% 7% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.17% 7% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain -21.60% N/A N/A 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.60% N/A N/A 9% F
Risk Return Profile  
Volatility (Standard Deviation) 80.37% N/A N/A 30% F
Risk Adjusted Return -26.88% N/A N/A 27% F
Market Capitalization 3.34M 35% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.10 83% B 91% A-
Price/Book Ratio 53.19 13% F 4% F
Price / Cash Flow Ratio -1.86 45% F 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 10.46% 63% D 70% C-
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.34 66% D 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.